Vimarsana
Biggest News Aggregation in the World

Page 44 - Wave Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Wave Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Wave Life Sciences Today - Breaking & Trending Today

Duchenne Muscular Dystrophy - Vimarsana News

Duchenne Muscular Dystrophy

Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter's investigational gene therapy asset SRP-9001 outside of the U.S. The asset is being evaluated in... Read More...

FDA says Voyager can trek on as it removes trial hold for Huntington's gene therapy test - Vimarsana News

FDA says Voyager can trek on as it removes trial hold for Huntington's gene therapy test

(Jensflorian CC BY-SA 3.0) The FDA is in a forgiving mood: After clearing uniQure’s gene therapy to restart trials today, it’s handing the same reprieve to Voyager Therapeutics. The biotech was slapped with a clinical hold on an IND for the program, VY-HTT01, because of issues with chemistry, manufacturing and controls (CMC). This marked a miserable time for the program, coming one year after Sanofi’s Genzyme unit pulled out of a collab for it. But now the FDA has lifted its hold on the gene therapy candidate in Huntington’s disease (HD), and “confirmed that the company ma...

Worldwide Antisense Oligonucleotide Therapeutics Industry to 2030 - Market Trends and Global Forecasts - Vimarsana News

Worldwide Antisense Oligonucleotide Therapeutics Industry to 2030 - Market Trends and Global Forecasts

Share this article Share this article ResearchAndMarkets.com's offering. Since the approval of Vitravene (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso (duchenne muscular dystrophy, March 2020), Vyondys 53 (duchenne muscular dystrophy, December 2019) and ...

Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond - Vimarsana News

Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond

KEY POINTS Virtual care has the potential to improve access to health care for people with Alzheimer disease and related dementias, especially in the context of the coronavirus disease 19 (COVID-19) pandemic. Videoteleconferencing is a well-studied means of virtual care that has successfully been used to remotely assess, diagnose and manage such patients. Successful telemedicine programs often have access to supplemental clinical information to aid in diagnosis and involve interdisciplinary teams to manage patient complexity. Evidence regarding direct-to-home virtual care for people with Alzh...

Source: cmaj.ca
WAVE Life Sciences (NASDAQ:WVE) - Looking Into WAVE Life Sciences's Return On Capital Employed - Vimarsana News

WAVE Life Sciences (NASDAQ:WVE) - Looking Into WAVE Life Sciences's Return On Capital Employed

WAVE Life Sciences (NASDAQ:WVE) reported Q4 sales of $9.44 million. Earnings fell to a loss of $30.31 million, resulting in a 11.92% decrease from last ...